Biogen Pharmachem Industries Limited
BSE: BIOGEN · Other Financial Services
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Biogen Pharmachem Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biogen Pharmachem Industries Limited is an Ahmedabad-based company primarily engaged in the trading and distribution of pharmaceutical products, active pharmaceutical ingredients, and industrial chemicals. The firm operates as a wholesale intermediary within the Indian pharmaceutical supply chain, focusing on logistics rather than manufacturing or research.
Business Model
The company generates revenue by sourcing chemical compounds and bulk drugs for supply to domestic manufacturers and healthcare providers. Its business model relies on efficient supply chain management and distribution logistics to meet market demand for generic chemical components.
Growth Outlook
Growth is primarily driven by the expanding demand for generic chemical components and pharmaceutical raw materials within the Indian market. The company aims to leverage its position in the wholesale trade segment to maintain its operational footprint.
Key Risks
- Supply Chain Volatility. The company is vulnerable to fluctuations in the availability and pricing of pharmaceutical raw materials and industrial chemicals.
- Regulatory Compliance. Changes in pharmaceutical distribution regulations or safety standards could impact operational costs and market access.
- Market Competition. As a small-cap trading entity, the company faces intense competition from larger, more integrated pharmaceutical distributors and direct manufacturers.
- Economic Sensitivity. Demand for industrial chemicals is highly correlated with the broader performance of the domestic pharmaceutical manufacturing sector.
Start your research today
Unlock AI insights, financials, peers and live data on Biogen Pharmachem Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
RETURN ON EQUITY
2.8%
TTM · standalone
P/E
11.0x
Q4 FY26 · standalone
NET PROFIT MARGIN
62.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Other Financial Services
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Biogen Pharmachem Industries LimitedBIOGEN | ₹29 Cr | 9.33 | — | 68.3% | 37.5% | 2.8% | — | -68.5% |
Stellant Securities (India) LimitedSTELLANT | ₹597 Cr | 26.16 | — | 909.8% | 18.8% | 243.0% | — | +78.8% |
The Investment Trust Of India LimitedTHEINVEST | ₹496 Cr | 14.89 | — | -22.3% | 20.0% | 5.1% | — | -37.8% |
Regency FincorpREGENCY | ₹407 Cr | 26.44 | — | 72.7% | 69.0% | 10.2% | — | +21.6% |
NDL VenturesNDLVENTURE | ₹403 Cr | 748.13 | — | — | — | 1.3% | — | +32.6% |
Shree Salasar Investment Ltd.SALSAIN | ₹256 Cr | 13.87 | — | 171.2% | 27.0% | 33.2% | — | — |
As of Q4 FY26
Financials
Biogen Pharmachem Industries Limited
BSE: BIOGEN · Other Financial Services
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Biogen Pharmachem Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biogen Pharmachem Industries Limited is an Ahmedabad-based company primarily engaged in the trading and distribution of pharmaceutical products, active pharmaceutical ingredients, and industrial chemicals. The firm operates as a wholesale intermediary within the Indian pharmaceutical supply chain, focusing on logistics rather than manufacturing or research.
Business Model
The company generates revenue by sourcing chemical compounds and bulk drugs for supply to domestic manufacturers and healthcare providers. Its business model relies on efficient supply chain management and distribution logistics to meet market demand for generic chemical components.
Growth Outlook
Growth is primarily driven by the expanding demand for generic chemical components and pharmaceutical raw materials within the Indian market. The company aims to leverage its position in the wholesale trade segment to maintain its operational footprint.
Key Risks
- Supply Chain Volatility. The company is vulnerable to fluctuations in the availability and pricing of pharmaceutical raw materials and industrial chemicals.
- Regulatory Compliance. Changes in pharmaceutical distribution regulations or safety standards could impact operational costs and market access.
- Market Competition. As a small-cap trading entity, the company faces intense competition from larger, more integrated pharmaceutical distributors and direct manufacturers.
- Economic Sensitivity. Demand for industrial chemicals is highly correlated with the broader performance of the domestic pharmaceutical manufacturing sector.
Start your research today
Unlock AI insights, financials, peers and live data on Biogen Pharmachem Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
RETURN ON EQUITY
2.8%
TTM · standalone
P/E
11.0x
Q4 FY26 · standalone
NET PROFIT MARGIN
62.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Other Financial Services
As of Q4 FY26